Discovery and Development of HIV-1 Entry Inhibitors That Target gp120

Antiviral Drugs: From Basic Discovery through Clinical Trials

Volumn , Issue , 2011, Pages 149-162

  Kadow, John F ^a   Bender, John ^a   Regueiro Ren, Alicia ^a   Ueda, Yasutsugu ^a   Wang, Tao ^a   Yeung, Kap Sun ^a   Meanwell, Nicholas A ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

BMS 488043 vs. BMS 378806 antiviral activity against HIV 1 B clade clinical isolates; HIV 1 entry inhibitor, discovery and development of target gp120; Other small molecule HIV inhibitors binding to gp120

Indexed keywords

EID: 84886012661     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470929353.ch11     Document Type: Chapter

References (52)

1. Gallo, R. C.; Montagnier, L. The discovery of HIV as the cause of AIDS. N. Engl. J. Med. 1990, 349, 2283-2285.
2. Pomerantz, R. J.; Horn; D. L. Twenty years of therapy for HIV-1 infection. Nat. Med. 2003, 9, 867-873.
3. Barré-Sinoussi, F. The early years of HIV research: integrating clinical and basic research. Nat. Med. 2003, 9, 844-846.
4. Merson, M. H. The HIV-AIDS pandemic at 25: the global response. N. Engl. J. Med. 2006, 354, 2414-2417.
5. DeClercq, E. Anti-HIV drugs: 25 compounds approvedwithin 25 years after the discovery of HIV. Int. J. Antimicrob. Agents 2009, 33, 307-320.
6. Baba, M.; Tanaka, H.; De Clercq, E.; Pauwels, R.; Balzarini, J.; Schols, D.; Nakashima, H.; Perno, C. F.; Walker, R. T.; Miyasaka, T. Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochem. Biophys. Res. Commun. 1989, 165, 1375-1381.
7. Pauwels, R.; Andries, K.; Desmyter, J.; Schols, D.; Kukla, M. J.; Breslin, H. J.; Raeymaeckers, A.; Van Gelder, J.;Woestenborghs, R.; Heykants, J.; et al. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 1990, 343, 470-474.
8. Sweeney, Z. K.; Klumpp, K. Improving non-nucleoside reverse transcriptase inhibitors for first-line treatment of HIV infection: the development pipeline and recent clinical data. Curr. Opin. Drug Discov. Dev. 2008, 11, 458-470.
9. Hammer, S. M.; Squires, K. E.; Hughes, M. D.; Grimes, J. M.; Demeter, L. M.; Currier, J. S.; Eron, J. J.; Feinberg, J. E.; Balfour, H. H.; Deyton, L. R.; et al. A controlled trial of two nucleoside analogs plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N. Engl. J. Med. 1997, 337, 725-733.
10. Hammer, S. M.; Eron; J., J., Jr.; Reiss, P.; Schooley, R. T.; Thompson, M. A.; Walmsley, S.; Cahn, P.; Fischl, M. A.; Gatell, J. M.; Hirsch, M. S.; et al. Antiretroviral treatment of adult HIV infection: recommendations of the International AIDS Society-USA panel. JAMA 2008, 300, 555-570.
11. Frampton, J. E.; Croom, K. F. Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination tablet. Drugs 2006, 66, 1501-1512.
12. Killingley, B.; Pozniak, A. The first once-daily single-tablet regimen for the treatment of HIV-infected patients. Drugs Today 2007, 43, 427-442.
13. Blair, W.; Spicer, T. P. World Patent Application WO-2001/96610, 2001.
14. Richman, D. D.;Morton, S. C.;Wrin, T.; Hellmann, N.; Berry, S.; Shapiro,M. F.; Bozzette, S. A. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004, 18, 1393-1401.
15. De Clercq, E. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res. 1998, 38, 153-179.
16. Blair,W. S.; Deshpande,M.; Fang, H.; Lin, P.-F.; Spicer, T. P.; Wallace, O. B.; Wang, H.; Wang, T.; Zhang, Z.; Yeung, K.-S. World Patent Application WO-2000/76521, 2000.
17. Wang, T.; Zhang, Z.;Wallace,O. B.; Deshpande,M.; Fang, H.; Yang, Z.; Zadjura, L.M.; Tweedie, D. L.; Huang, S.; Zhao, F.; et al. Discovery of 4-benzoyl-1-[(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2-(R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions. J. Med. Chem. 2003, 46, 4236-4239.
18. Meanwell, N. A.; Wallace, O. B.; Wang, H.; Deshpande, M.; Pearce, B. C.; Trehan, A.; Yeung, K.-S.; Qiu, Z.; Wright, J. J. K.; Robinson, B. A.; et al. Inhibitors of HIV-1 attachment: 3. A preliminary survey of the effect of structural variation of the benzamide moiety on antiviral activity. Bioorg. Med. Chem. Lett. 2009, 19, 5136.
19. Wang, T.; Kadow, J. F.; Zhang, Z.; Yin, Z.; Gao, Q.; Wu, D.; DiGuigno Parker, D.; Yang, Z.; Zadjura, L.; Robinson, B. A.; et al. Inhibitors of HIV-1 attachment: 4. A study of the effect of piperazine substitution patterns on antiviral potency in the context of indole-based derivatives. Bioorg. Med. Chem. Lett. 2009, 19, 5140.
20. Meanwell, N. A.; Wallace, O. B.; Fang, H.; Wang, H.; Deshpande, M.; Wang, T.; Yin, Z.; Zhang, Z.; Pearce, B. C.; James, J.; et al. Inhibitors of HIV-1 attachment: 2. An initial survey of indole substitution patterns. Bioorg. Med. Chem. Lett. 2009, 19, 1977-1981.
21. Wang, T.; Yin, Z.; Zhang, Z.; Bender, J. A.; Yang, Z.; Johnson, G.; Yang, Z.; Zadjura, L. M.; D'Arienzo, C. J.; Parker, D. D.; et al. Inhibitors of HIV-1 attachment: 5. An evolution from indole to azaindoles leading to the discovery of BMS-488043, a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects. J. Med. Chem. 2009, 52, 7778-7787.
22. Zhang, Z.; Yang, Z.;Meanwell, N. A.; Kadow, J. F.;Wang, T. A general method for the preparation of 4-and 6-azaindoles. J. Org. Chem. 2002, 67, 2345-2347.
23. Guo, Q.; Ho, H.-T.; Dicker, I.; Fan, L.; Zhou, N.; Friborg, J.; Wang, T.; McAuliffe, B. V.; Wang, H.-G. H.; Rose, R. E.; et al. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J. Virol. 2003, 77, 10528-10536.
24. Lin, P.-F.; Blair, W.; Wang, T.; Spicer, T.; Guo, Q.; Zhou, N.; Gong, Y.-F.; Wang, H.-G. H.; Rose, R.; Yamanaka, G.; et al. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. Natl. Acad. Sci. USA 2003, 100, 11013-11018.
25. Kwong, P. D.; Wyatt, R.; Robinson, J.; Sweet, R. W.; Sodroski, J.; Hendrickson, W. A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393, 648-659.
26. Benoit, S.; Gingras, S.; Soundararajan, N., inventors; Bristol-Myers Squibb Co., assignee. Process for the preparation of antiviral 7-azaindole derivatives. WO 2003082289 A1, Oct. 9, 2003.
27. Yang, Z.; Zadjura, L.; D'Arienzo, C.; Marino, A.; Santone, K.; Klunk, L.; Greene, D.; Lin, P.-F.; Colonno, R.; Wang, T.; et al. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics. Biopharm. Drug Dispos. 2005, 26, 387-402.
28. Hanna, G.; Lalezari, J.; Hellinger, J.; Wohl, D.; Masterson, T.; Fiske, W.; Kadow, J.; Lin, P.-F.; Giordano, M.; Colonno, R.; Grasela D. Antiviral activity, safety, and tolerability of a novel, oral small-molecule HIV-1 attachment inhibitor, BMS-488043, in HIV-1 infected subjects. 11th Conference Retroviruses and Opportunistic Infection, San Francisco, Feb. 8-11, 2004. Abstract 141.
29. Ho, H.-T.; Fan, L.; Nowicka-Sans, B.; McAuliffe, B.; Li, C.-B.; Yamanaka, G.; Zhou, N.; Fang, H.; Dicker, I.; Dalterio, R.; et al. Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events. J. Virol. 2006, 80, 4017-4025.
30. Lin, P. F.; Ho, H. T.; Gong, Y. F.; Dicker, I.; Zhou, N.; Fan, L.; McAuliffe, B.; Kimmel, B.; Nowicka-Sans, B.; Wang, T.; et al. Characterization of a small molecule HIV-1 attachment inhibitor BMS-488043: virology, resistance, and mechanism of action. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, Feb. 8-11, 2004. Abstract 534.
31. Lin, P. F.; Ho, H. T.; Fan, L.; Li, C. B.; Nowicka-Sans, B.; McAuliffe, B.; Zhou, N.; Dalterio, R.; Gong, Y.; Eggers, B.; et al. Inhibition mechanism of small molecule HIV-1 attachment inhibitors. 12th Conference on Retroviruses and Opportunistic Infections, Boston, Feb. 22-25, 2005. Abstract 544.
32. Liu, W.; Patel, S. S.; Cuniere, N.; Lear, Y.; Deshpande, P. P.; Simon, J. N.; Lai, C.; Pullockaran, A. J.; Soundararajan, N.; Bien, J. T., inventors; Bristol-Myers Squibb Co., assignee. Method of preparation of azaindole derivatives. US 2007032503 A1, Feb. 8, 2007.
33. Yang, Z.; Zadjura, L. M.; Marino, A. M.; D'Arienzo, C. J.; Malinowski, J.; Gesenberg, C.; Lin, P.-F.; Colonno, R. J.; Wang, T.; Kadow, J. F.; et al. J. Pharm. Sci. 2010, 99, 2135-2152.
34. Fakes, M. G.; Vakkalagadda, B. J.; Qian, F.; Desikan, S.; Gandhi, R. B.; Lai, C.; Hsieh, A.; Franchini, M. K.; Toale, H.; Brown, J. Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches. Int. J. Pharm. 2009, 370, 167-174.
35. Tobyn, M.;Brown, J.; Dennis, A. B.; Fakes,M.; Gao, Q.;Gamble, J.; Khimyak, Y. Z.; McGeorge, G.; Patel, C.; Sinclair,W.; Timmins, P.Amorphous drug-PVP dispersions: application of theoretical, thermal, and spectroscopic analytical techniques to the study of a molecule with intermolecular bonds in both the crystalline and pure amorphous state. J. Pharm. Sci. 2009 (online early disclosure).
36. Heimbach, T.; Oh, D.-M.; Li, L. Y.; Rodriguez-Hornedo, N.; Garcia, G.; Fleisher, D. Enzyme-mediated precipitation of parent drugs from their phosphate prodrugs. Int. J. Pharm., 2003, 261, 81-92.
37. Heimbach, T.; Oh, D.-M.; Li, L. Y.; Forsberg, M.; Savolainen, J.; Leppaenen, J.; Matsunaga, Y.; Flynn, G.; Fleisher, D. Absorption rate limit considerations for oral phosphate prodrugs. Pharm. Res. 2003, 20, 848-856.
38. Ueda, Y.; Matiskella, J. D.; Golik, J.; Connolly, T. P.; Hudyma, T. W.; Venkatesh, S.; Dali, M.; Kang, S.-H.; Barbour, N.; Tejwani, R.; et al. Phosphonooxymethyl prodrugs of the broad spectrum antifungal azole, ravuconazole: synthesis and biological properties. Bioorg. Med. Chem. Lett. 2003, 13, 3669-3672.
39. Ueda, Y.; Connolly, T. P.; Wang, T.; Chen, C.-P. H.; Yeung, K.-S.; Zheng, M.; Bender, J.; Yang, Z.; Lin, P. F.; Colonno, R. P.; et al. Unpublished results.
40. Ueda, Y.; Connolly, T. P.; Kadow, J. F.; Meanwell, N. A.; Wang, T.; Chen, C.-P. H.; Yeung, K.-S.; Zhang, Z.; Leahy, D. K.; Pack, S. K.; et al., inventors; Bristol-Myers Squibb Co., assignee. Prodrugs based on bicyclic nitrogen-containing heterocyclic antiviral agents having substituted piperazine or piperidine rings. U.S. Patent Application 2005209246 A1, Sept. 22, 2005.
41. Zhu, Z.;Chen, H.-G.; Goel,O. P.; Chan,O.H.; Stilgenbauer, L. A.; Stewart, B. H. Phosphate prodrugs of PD 154075. Bioorg. Med. Chem. Lett. 2000, 10, 1121-1124.
42. Zheng, M., et al. Unpublished results.
43. Yeung, K. S.; Kadow, J. F.; Meanwell, N. A. et. al. Unpublished results.
44. Kadow, J.; Wang, H.-G. H.; Lin, P.-F. Small-molecule HIV-1 gp120 inhibitors to prevent HIV-1 entry: an emerging opportunity for drug development. Curr. Opin. Invest. Drugs 2006, 7, 721-726.
45. Wang, J.; Le, N. Heredia, A.; Song, H.; Redfield, R.;Wang, L.-X. Modification and structure-activity relationship of a small molecule HIV-1 inhibitor targeting the viral envelope glycoprotein gp120. Org. Biomol. Chem. 2005, 3, 1781-1786.
46. Zhao,Q.; Ma, L.; Jiang, S.; Liu, S.; He,Y.; Strick,N.; Neamati, N.; Debnath, A. K. Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIVentry inhibitors that prevent gp120 binding to CD4. Virology 2005, 339, 213-225.
47. Middleton, D. S.;Mowbray,C. E.; Stephenson, P. T.;Williams, D. H., inventors; Pfizer, Inc., assignee. Preparation of piperazine derivatives for use in pharmaceutical compositions for the treatment of HIV infection. U.S. Patent Application 2005043300, Feb. 24, 2005.
48. Fenwick, D. R.; Gillmore, A. T.; Platts, M. Y., inventors; Pfizer Inc., assignee. Preparation of a crystalline form of 5-[[(1S)-2-((2R)-4-benzoyl-2-methylpiperazin-1-yl)-1-methyl-2-oxoethyl]oxy]-4-methoxypyridine-2-carboxylic acid methylamide for the treatment of HIV. PCT Patent Application. WO2006085199, Aug. 17, 2006.
49. Parkinson,T.; Stephenson, P.; Pickford, C.;Tran, D.;Williams, D.; Fenwick, D.; Fok-Seang, J.; Gardner, I.;Westby, M.;Middleton, D.; Perros, M. Characterization of a novel series of gp120 inhibitors. International Conference on Antiretroviral Research, 2008. Abstract A-24.
50. Chan, P. L. S.; Schaick, E.; Langdon, J. D.; Parkinson, T.; McFadyen, L. PK-PD modeling to support go/no go decisions for a novel gp120 inhibitor. Population Approach Group in Europe, 2007. Abstract 1162.
51. Lu, R.-J.; Tucker, J. A.; Zinevitch, T.; Kirichenko, O.; Konoplev, V.; Kuznetsova, S.; Sviridov, S.; Pickens, J.; Tandel, S.; Brahmachary, E.; et al. Design and synthesis of human immunodeficiency virus entry inhibitors: sulfonamide as an isostere for the a-ketoamide group. J. Med. Chem. 2007, 50, 6535-6544.
52. Srivastava, I. K.; Sharma, V.; Barnett, S. W.; Ulmer, J., inventors; Chiron Corp., assignee. Env polypeptide complexes and methods of use. PCT Patent ApplicationWO2005121175, Dec. 22, 2005.